# An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)

> **NCT01224093** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 219 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT01224093
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224093, "An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01224093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*